Zydus Cadila takes yet another step towards diabetes care with the launch of an affordable oral anti-diabetic agent, Vinglyn (Vildagliptin) & Vinglyn M (Vildagliptin plus metformin). The drug belongs to the class of oral anti-diabetic agents, known as DPP4 inhibitors, which have shown promise in achieving glycaemic control without deterioration in beta cell function and are one of the recent advancements in diabetes care and management. Vinglyn and Vinglyn M will be marketed by Zydus Healthcare Ltd.
Priced at just Rs 4.95 per tablet, which is almost l/6th the price at which the patented Vildagliptin was initially launched in India, Vinglyn is now one of the most affordable brands of Vildagliptin for diabetic patients in India.
Commenting on the launch. Dr. Sharvil Patel, Managing Director, Zydus Cadila, said, "Diabetes is becoming a major health burden globally. Fortifying our tight against diabetes, our aim is to make therapies affordable and accessible to patients from across sections of society. With Vinglyn, we believe that we have once again been able to offer this. The access to one of the most affordable gliptin therapies will help a large number of patients suffering from Type II diabetes, in India.”
The incidence of diabetes is an alarming one with the number of diabetics in the world estimated to be over 463 million. With a patient population of almost 77 million diabetics in India, access to affordable therapy is vital for the effective management of the disease.
